---
title: "Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Generic, brand name and therapeutic class of product. Topics: Manufacturer: uniQure; Nonproprietary name and development code; Nonproprietary name: WHO proposed International Nonproprietary Name and substance description; Product name, product code, and descriptive name in the EU clinical trial record; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: uniQure

> “Ifezuntirgene inilparvovec (also known as AMT-130) is our novel gene therapy candidate for the treatment of Huntington’s disease, which utilizes our proprietary, gene-silencing miQURE® platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment.”

Source: [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm)

<a id="topic-2.1.2.1-2"></a>

### Nonproprietary name and development code

> “Our investigational gene therapy candidate ifezuntirgene inilparvovec (AMT-130) consists of an AAV5 vector carrying an artificial micro-RNA specifically tailored to silence the huntingtin gene, leveraging our proprietary miQURE™ silencing technology.”

Source: [uniQure Huntington's disease program page](https://www.uniqure.com/programs-pipeline/huntingtons-disease)

<a id="topic-2.1.2.1-3"></a>

### Nonproprietary name: WHO proposed International Nonproprietary Name and substance description

> “a recombinant, replication deficient adeno-associated virus serotype 5 (AAV5) vector encoding a microRNA (miRNA) targeting the exon 1 of human huntingtin protein (HTT) mRNA (miHTT).”

Source: [WHO Proposed INN List 125 (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.1-4"></a>

### Product name, product code, and descriptive name in the EU clinical trial record

| Field | Quoted record |
| --- | --- |
| Product name | “rAAV5-miHTT” |
| Product code | “AMT-130” |
| Other descriptive name | “ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE” |

Source: [EU Clinical Trials Register 2020-001461-36](https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001461-36/PL)

<a id="topic-2.1.2.1-5"></a>

### Brand name

No evidence found.

<a id="topic-2.1.2.1-6"></a>

### Therapeutic class: AAV-based gene therapy using the miQURE gene-silencing platform

> “AMT-130 is the first AAV-based gene therapy for the treatment of Huntington’s disease to have entered into clinical development.”
> “miQURE-based gene therapy candidates, such as AMT-130, incorporate proprietary, therapeutic miRNA constructs that can be delivered using AAVs to potentially provide long-lasting activity.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.1-7"></a>

### Licensing: miQURE platform technology from Cold Spring Harbor Laboratory

> “Our miQURE gene silencing platform, based on exclusively licensed technology from Cold Spring Harbor Laboratory (“CSHL”), is designed to degrade mutated genes without producing a “passenger strand” thereby mitigating potential off-target toxicity and induce silencing of the mutated gene in the entire target organ through secondary exosome-mediated delivery.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.1-8"></a>

### Intellectual property: patent families covering AMT-130 and its formulation

> “We own three published patent families directed to gene therapy treatment of Huntington’s disease, including AMT-130 and its formulation.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-2.1.2.1-9"></a>

### Manufacturing: contract manufacturing by Genezen after the 2024 facility sale

> “Under the proposed transaction, Genezen will be responsible for manufacturing global commercial supply of HEMGENIX® for CSL and providing development and manufacturing services to support uniQure’s investigational gene therapies.”

Source: [uniQure press release, sale of manufacturing facility to Genezen (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-sale-commercial-manufacturing-facility-genezen)

> “Additionally, this transaction provides uniQure continued and preferred access to world-class gene therapy manufacturing capabilities to advance our gene therapy product candidates and enables us to focus our future investments on projects that have the potential to meaningfully increase shareholder value.”

Source: [uniQure press release, closing of sale to Genezen (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-closing-sale-manufacturing-facility-genezen)

> “We currently rely and expect to continue to rely on third parties to manufacture our product candidates, and these third parties may not perform satisfactorily or may fail to comply with these regulations or maintain these approvals.”
> “Our proprietary manufacturing processes leveraging insect cells and baculoviruses to produce AAV-based gene therapies are highly complex and regularly subject to variation or production difficulties.”

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/executive-summary.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
